Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Blood (2020) 136 (Supplement 1): 58–59.

https://doi.org/10.1182/blood-2020-135929

Published: 2020

Journal Articles

Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML

Ivy Abraham, MD, Garth Rauscher, PhD MPH, Anand Ashwin Patel, MD, Wendy Stock, MD, Maryam Zia, MD, Sushma Bharadwaj, MD, Koosha Paydary, MD, Maria Acevedo-Mendez, John P Galvin, MDMS,MPH, William Pearse, MD, Jessica K. Altman, John G. Quigley, Priya Rajakumar, MD, Melissa L. Larson, MD, Irum Khan, MD

Blood (2019) 134 (Supplement_1): 3413.

https://doi.org/10.1182/blood-2019-124974

Published: 2019

Journal Articles

Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)

Gail J. Roboz, MD, Melissa L. Larson, MD, S. Eric Rubenstein, MD, Scott R Solomon, MD, Gary J. Schiller, MD, Qi An, Emaryn Mancino, Michael Chiarella, Arthur C. Louie, Tara L Lin, MD

Blood (2018) 132 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2018-99-111537

Published: 2018

Journal Articles

Bridging to Second Allogeneic Peripheral Blood Stem Cell Transplantation with Nelarabine in a Patient with Multiply Relapsed/Refractory T-Cell ALL

Jacqueline Baptista, RN, APN, Eris Tollkuci, PharmD, Sunita Nathan, MD, John J. Maciejewski, MD PhD, Melissa L. Larson, MD, Gorgun Akpek, MD MHS

Blood (2016) 128 (22): 5200.

https://doi.org/10.1182/blood.V128.22.5200.5200

Published: 2016

Journal Articles

A Report On a Phase 2 Trial Of Combination Therapy With Lenalidomide and Azacitidine In Patients With Non-Del 5q, Low Risk MDS

Jamile M. Shammo, MD, Kent W. Christopherson, II, PhD, Reem Karmali, MD, Melissa L. Larson, MD, Michelle Balla, Parameswaran Venugopal, MD

Blood (2013) 122 (21): 5232.

https://doi.org/10.1182/blood.V122.21.5232.5232

Published: 2013

Journal Articles

Timed Sequential Induction Therapy with Cytarabine and Mitoxantrone In Acute Myeloid Leukemia (AML): A Well-Tolerated Regimen with High Response Rates In Older Patients and Transformed AML.

Sheena Sahota, M.D., Melissa L Larson, MD, Margaret C Keller, ACNP, Jamile M. Shammo, MD, Allison Zindell, Bharathi Muthusamy, Stephanie A. Gregory, MD, Parameswaran Venugopal, MD

Blood (2010) 116 (21): 1068.

https://doi.org/10.1182/blood.V116.21.1068.1068

Published: 2010

Journal Articles

Favorable Outcome In Patients with Poor Prognosis Acute Myeloid Leukemia (AML) Using a 2-Day Induction Regimen Incorporating High Dose Cytarabine and Mitoxantrone.

Melissa L Larson, MD, Sheena Sahota, M.D., Margaret C Keller, ACNP, Bharathi Muthusamy, Allison Zindell, Jamile M. Shammo, MD, Stephanie A. Gregory, MD, Parameswaran Venugopal, MD

Blood (2010) 116 (21): 1069.

https://doi.org/10.1182/blood.V116.21.1069.1069

Published: 2010

Journal Articles

Phase II Study of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Reem Karmali, MD, Andrew Manson, Katherine Bueschel, MD, Kathryn Shell, Stephanie A. Gregory, MD, Teresa O'Brien, Jamile M. Shammo, MD, Melissa L Larson, MD, Parmeswaran Venugopal, MD

Blood (2010) 116 (21): 3947.

https://doi.org/10.1182/blood.V116.21.3947.3947

Published: 2010

Journal Articles

Lenalidomide-Induced Cytopenias In Patients with MDS Are Negatively Impacted by Reduced Glomerular Filtration Rate

Arlene Dawravoo, MD, Reem Karmali, MD, Amy Rizman, Stephanie A. Gregory, MD, Melissa L Larson, MD, Parameswaran Venugopal, MD, Jamile M. Shammo, MD

Blood (2010) 116 (21): 4958.

https://doi.org/10.1182/blood.V116.21.4958.4958

Published: 2010

Journal Articles

Tolerability of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Andrew Manson, Reem Karmali, MD, Irene Dehghan-Paz, MD, Eduardo Braun, MD, Teresa O'Brien, Stephanie A. Gregory, MD, Jamile M. Shammo, MD, Melissa L Larson, MD, Parmeswaran Venugopal, MD

Blood (2010) 116 (21): 4918.

https://doi.org/10.1182/blood.V116.21.4918.4918

Published: 2010

Journal Articles

Gain of CD20 Target Cell Surface Receptor Expression During Serum-Free Ex Vivo Culture of CD19 + CD5 + B-Cells In a Sub-Population of Early Stage (Rai 0/1) Chronic Lymphocytic Leukemia Patients

Robin Frank, BS, Hugo Jimenez, Sucheta Jagan, MS, Lydia Luy Tan, BS, Laura A Paganessi, MA, Melissa L Larson, MD, Parameswaran Venugopal, MD, Stephanie A. Gregory, MD, Kent W Christopherson, II, PhD

Blood (2010) 116 (21): 2000.

https://doi.org/10.1182/blood.V116.21.2000.2000

Published: 2010

Journal Articles

Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.

Susan O'Brien, MD, Gary Schiller, Lloyd E. Damon, MD, John Lister, MD, Farhad Ravandi, MD, Dan Douer, MD, Aisha Masood, MD, Dina Ben-Yehuda, Jacob M. Rowe, MD, Nicola Gökbuget, Walter Aulitzky, Wendy Stock, MD, Steven Coutre, MD, Leonard Heffner, MD, Melissa L. Larson, MD, Karen Seiter, MD, Anne E Hagey, MD, Steven R. Deitcher, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 3088.

https://doi.org/10.1182/blood.V114.22.3088.3088

Published: 2009

Journal Articles

Early Signs of Tolerability and Activity in a Phase 2 Study of Weekly Vincristine Sulfate Liposomal Injection (VSLI, MarqiboÒ) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-Leukemia Treatment Lines

Susan O’Brien, M.D., Lloyd E. Damon, MD, Melissa L. Larson, MD, Gary Schiller, Wendy Stock, MD, Deborah A Thomas, MD, Biao Lu, Michael S. Imperiale, MD, Hagop M Kantarjian

Blood (2008) 112 (11): 3959.

https://doi.org/10.1182/blood.V112.11.3959.3959

Published: 2008

Journal Articles

Effective Remission Induction for AML Using Two Days of Chemotherapy: Older Patients Tolerate and Respond Equally Well

Neel B. Shah, MD, Melissa L. Larson, MD, Nitin Goyal, Ann M. Thomas, Jamile M. Shammo, MD, John J. Maciejewski, MD, PhD, Stephanie A. Gregory, MD, Parameswaran Venugopal, MD

Blood (2008) 112 (11): 4004.

https://doi.org/10.1182/blood.V112.11.4004.4004

Published: 2008

Journal Articles

Efficacy of a Two Day Induction Regimen for De Novo and Secondary AML with Intermediate and Adverse Cytogenetic Profiles

Melissa L. Larson, MD, Ann M. Thomas, Nitin Goyal, Jamile M. Shammo, MD, John J. Maciejewski, MD, PhD, Stephanie A. Gregory, MD, Parameswaran Venugopal, MD

Blood (2008) 112 (11): 4027.

https://doi.org/10.1182/blood.V112.11.4027.4027

Published: 2008

Journal Articles

Tolerability of An Effective Two Day Induction Regimen for Newly Diagnosed AML

Melissa L. Larson, MD, Nitin Goyal, Ann M. Thomas, Jamile M. Shammo, MD, John J. Maciejewski, MD, PhD, Stephanie A. Gregory, MD, Parameswaran Venugopal, MD

Blood (2008) 112 (11): 4035.

https://doi.org/10.1182/blood.V112.11.4035.4035

Published: 2008

Journal Articles

Cytogenetic Analysis and FISH in the Evaluation of Patients with MDS: A Retrospective Analysis of Concordance Rate, Utility and Benefit of Performing Both Studies Simultaneously

Jami le Shammo, Alla Gimelfarb, Wei-Tong Hsu, Irene Dehghan- Paz, Parameswaran Venugopal, Melissa L. Larson, MD, Henry C. Fung, Mohamed Farhat, Amy Rizman, Jerome Loew, Stephanie A. Gregory

Blood (2008) 112 (11): 3630.

https://doi.org/10.1182/blood.V112.11.3630.3630

Published: 2008

Journal Articles

Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Pateints (pts) with Advanced Chronic Lymphoctic Leukemia (CLL): A Comparative Study.

Antonio Jimenez, MD, Mohamed I. Farhat, MD, Stephanie A. Gregory, MD, Mohamad Kassar, MD, Alla Gimelfarb, MD, Marta Batus, MD, Julie Nangia, MD, Neel Shah, MD, Parameswaran Venugopal, MD, Melissa L. Larson, MD, Kent W. Christopherson, PHD, Henry C. Fung, MD

Blood (2007) 110 (11): 5044.

https://doi.org/10.1182/blood.V110.11.5044.5044

Published: 2007

Journal Articles

Abnormally High Levels of Circulating CD34 + CD38 − , CD34 + CD38 + , and CD10 + Hematopoietic Stem and Progenitor Cells in the Peripheral Blood of B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Suggest the Presence of Additional Therapeutic Target Cells.

Kent W. Christopherson, PhD, Laura A. Paganessi, MA, Darilyn R. Rhoades, RN, Hortense M. Dillon, CMA, Sefer Gezer, MD, Melissa L. Larson, MD, Henry C. Fung, MD, Stephanie A. Gregory, MD

Blood (2007) 110 (11): 4711.

https://doi.org/10.1182/blood.V110.11.4711.4711

Published: 2007

NARROW

Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML

Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)

Bridging to Second Allogeneic Peripheral Blood Stem Cell Transplantation with Nelarabine in a Patient with Multiply Relapsed/Refractory T-Cell ALL

A Report On a Phase 2 Trial Of Combination Therapy With Lenalidomide and Azacitidine In Patients With Non-Del 5q, Low Risk MDS

Timed Sequential Induction Therapy with Cytarabine and Mitoxantrone In Acute Myeloid Leukemia (AML): A Well-Tolerated Regimen with High Response Rates In Older Patients and Transformed AML.

Favorable Outcome In Patients with Poor Prognosis Acute Myeloid Leukemia (AML) Using a 2-Day Induction Regimen Incorporating High Dose Cytarabine and Mitoxantrone.

Phase II Study of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Lenalidomide-Induced Cytopenias In Patients with MDS Are Negatively Impacted by Reduced Glomerular Filtration Rate

Tolerability of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Gain of CD20 Target Cell Surface Receptor Expression During Serum-Free Ex Vivo Culture of CD19 + CD5 + B-Cells In a Sub-Population of Early Stage (Rai 0/1) Chronic Lymphocytic Leukemia Patients

Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.

Early Signs of Tolerability and Activity in a Phase 2 Study of Weekly Vincristine Sulfate Liposomal Injection (VSLI, MarqiboÒ) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-Leukemia Treatment Lines

Effective Remission Induction for AML Using Two Days of Chemotherapy: Older Patients Tolerate and Respond Equally Well

Efficacy of a Two Day Induction Regimen for De Novo and Secondary AML with Intermediate and Adverse Cytogenetic Profiles

Tolerability of An Effective Two Day Induction Regimen for Newly Diagnosed AML

Cytogenetic Analysis and FISH in the Evaluation of Patients with MDS: A Retrospective Analysis of Concordance Rate, Utility and Benefit of Performing Both Studies Simultaneously

Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Pateints (pts) with Advanced Chronic Lymphoctic Leukemia (CLL): A Comparative Study.

Abnormally High Levels of Circulating CD34 + CD38 − , CD34 + CD38 + , and CD10 + Hematopoietic Stem and Progenitor Cells in the Peripheral Blood of B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Suggest the Presence of Additional Therapeutic Target Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only